Rebel Medicine Inc — SEC Form D Filing

Rebel Medicine Inc filed an SEC Form D on June 3, 2026, reporting $8.79M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
June 3, 2026
Amount reported
$8.79M
Round stage
Pre-Seed
Industry
Health Care
Website
https://www.rebelmedicine.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Acute pain management currently relies heavily on opioids, which can lead to addiction and other negative side effects. Additionally, rising healthcare costs and unequal access prevent many patients from receiving necessary treatments.

Solution

Rebel Medicine is developing Alevatrix™, a best-in-class long-acting local anesthetic for non-opioid postoperative pain management, to offer a more accessible and safer alternative for acute pain relief.

Verdict

Investors said yes because Rebel Medicine presented a compelling solution to a pressing problem, namely opioid dependency in pain management, not because they had a robust market entry strategy or a clear buyer. They were betting on the urgent need for safer alternatives in healthcare, while the limited upside lies in the competitive landscape of anesthetics and potential adoption hurdles within a regulated market. This cleared because stakeholders recognized the opioid crisis as a significant risk, not because Rebel Medicine had demonstrated a clear path to commercialization.

Source: SEC EDGAR Form D filing